Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

UNKNOWN 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1

Conditions

Stomach Neoplasms 9Colorectal Neoplasms 4Head and Neck Neoplasms 3Colonic Neoplasms 3Squamous Cell Carcinoma of Head and Neck 2Gallbladder Neoplasms 2Esophageal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Hepatocellular 2Uterine Cervical Neoplasms 1Stage IA Pancreatic Adenocarcinoma 1Recurrence 1Rectal Neoplasms 1Pancreatic Neoplasms 1Mouth Neoplasms 1Lung Neoplasms 1HER2-positive Gastric Cancer 1Fruquintinib 1For Patients With Colorectal Cancer Liver Metastases Who Were Not Able to Curative Surgical Resection.Focused on the Treatment Effect With the Quintuple Method 1Extrapancreatic Neuroendocrine Tumor 1Cholangiocarcinoma 1Biliary Tract Neoplasms 1Adenoma, Islet Cell 1

Interventions

Thalidomide 1Temozolomide 1Tegafur 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Extrapancreatic Neuroendocrine Tumor × Tegafur × Clear all
NCT03204032 2017-06-29

A Study of Tegafur Combined With Temozolomide Versus Tegafur Combined With Temozolomide and Thalidomide in Subjects With Advanced Extrapancreatic Neuroendocrine Tumor

ChineseAMS

Phase 2 Unknown
60 enrolled
EndocrineGastrointestinalNET

Extrapancreatic Neuroendocrine Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡